|
- 品牌：EnkiLife
- 产地：中国
- 型号：50μg
- 货号：PEH1676
- 纯度：95
- 价格： ￥760/支
- 发布日期： 2025-06-23
- 更新日期： 2025-06-23
| 产地 | 中国 |
| 品牌 | EnkiLife |
| 货号 | PEH1676 |
| 用途 | |
| 包装规格 | 50μg |
| 纯度 | 95% |
| CAS编号 | |
| 是否进口 | 否 |
| 产品名称 | Recombinant Human TNF alpha (C-6His) |
| 英文名称 | TNF alpha/TNFSF2/TNFα |
| 纯度 | Greater than 95% as determined by reducing SDS-PAGE |
| 内毒素 | <1 EU/μg as determined by LAL test. |
| 蛋白构建 | Recombinant Human Tumor Necrosis Factor Alpha is produced by our E.coli expression system and the target gene encoding Val77-Leu233 is expressed with a 6His tag at the C-terminus. |
| Accession | P01375 |
| 表达宿主 | E.coli |
| 种属 | Human |
| 预测分子量 | 18.5 KDa |
| 制剂 | Lyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, pH 8.0. |
| 运输方式 | The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below. |
| 稳定性&储存 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
| 分子别名 |
| Tumor Necrosis Factor; Cachectin; TNF-Alpha; Tumor Necrosis Factor Ligand Superfamily Member 2; TNF-a; TNF; TNFA; TNFSF2 |
| 背景介绍 |
| Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo. |
注意事项
本司产品仅用于科研,不用于临床诊断